When will the NTLA-2002 pivotal trial start? | Categorical | | | 7 months ago | |
Will Intellia finalize NTLA-2002 dosing for pivotal trials by September 30, 2024? | Binary | | | 7 months ago | |
Will Intellia announce a partnership for NTLA-2002 commercialization by December 31, 2024? | Binary | | | 7 months ago | |
Which dosing will Intellia select for NTLA-2002 pivotal trials by September 30, 2024? | Categorical | | | 7 months ago | |
At which major medical conference will Intellia present NTLA-2002 data by December 31, 2024? | Categorical | | | 7 months ago | |
Will Intellia's CRISPR therapy be FDA approved for ATTR-CM by end of 2025? | Binary | | | 1 month ago | |
Will NTLA-2002 receive Fast Track designation from FDA by December 31, 2024? | Binary | | | 7 months ago | |
Will Intellia's CRISPR therapy enter Phase 2 trials for ATTR-CM by mid-2025? | Binary | | | 1 month ago | |
Will Intellia's CRISPR therapy outperform Alnylam's siRNA therapy by end of 2025? | Binary | | | 1 month ago | |
What level of transthyretin reduction will Intellia's CRISPR therapy achieve by end of 2025? | Categorical | | | 1 month ago | |
What market share will Intellia's CRISPR therapy hold over Alnylam's by end of 2026? | Categorical | | | 1 month ago | |
What level of cardiomyopathy improvement will Intellia's CRISPR therapy show by end of 2025? | Categorical | | | 1 month ago | |
